Sesen launches benchmark program for AI life sciences translation

Sesen has launched a benchmark program to help pharmaceutical, biotech, medical device and CRO teams test whether its SesenGPT workflows can improve translation quality, speed and cost using their own content. The program is designed to replace broad AI claims with measurable comparisons on accuracy, terminology, review effort and total cost.

Why it matters: - Life sciences teams need translation that is accurate, compliant and cost-efficient. - SesenGPT Benchmark Program is designed to show whether AI-enabled workflows can improve those outcomes without weakening quality controls. - The program focuses on regulated content where errors in terminology, numbers or instructions can have real operational and compliance consequences.

What happened: - Sesen announced the launch of its SesenGPT Life Sciences Translation Benchmark Program. - The program is aimed at pharmaceutical, biotechnology, medical device and contract research organization teams. - Participants can test SesenGPT-powered translation workflows against their existing processes using representative clinical, regulatory, scientific and technical content. - The evaluation uses the customer’s own content and agreed quality criteria.

The details: - The benchmark compares translation accuracy, terminology consistency, human review effort, turnaround and total cost per accepted deliverable. - Evaluations can include representative documents, selected language pairs and agreed quality requirements. - The program assesses six dimensions: translation accuracy and quality, terminology and regulatory relevance, numerical and technical precision, human review and correction effort, turnaround and workflow efficiency, and total translation cost. - Qualified reviewers assess translation quality using agreed criteria. - Reviewers are kept separate from translation production where practicable. - The evaluation accounts for content complexity, language pairs, reference materials and review requirements. - The program uses SesenGPT, Sesen’s controlled AI translation infrastructure. - The workflow combines life sciences-adapted AI, customer-specific terminology, approved translation memory, specialized medical linguists and structured quality assurance. - The program supports clinical trial materials, regulatory submissions, medical device documentation, pharmaceutical labeling, pharmacovigilance materials, biotechnology documentation, eCOA and digital health content. - Sesen says the benchmark is not meant to assume AI will beat every existing workflow. - The goal is to identify where AI-enabled translation offers measurable advantages and where human expertise remains necessary.

Between the lines: - Sesen is positioning the program as a practical test, not a blanket replacement for established translation vendors or internal review processes. - The approach reflects a broader market shift: buyers want proof of performance on their own materials rather than generic AI promises. - The focus on baseline data, reviewer separation and controlled workflows signals an emphasis on auditability and comparability.

What's next: - Participating organizations receive a findings summary covering performance measures, translation quality observations, cost and efficiency comparisons and recommended next steps. - Sesen says the findings can help teams decide where AI-enabled translation fits, where internal review can be reduced and where human-led translation is still preferable. - Benchmark scope, schedule and participation terms are set based on each organization’s needs. - Confidentiality requirements and content-transfer agreements are established before materials are exchanged. - More information is available at the benchmark program page.

The bottom line: - Sesen is offering life sciences companies a structured way to measure whether AI translation can improve quality and economics without compromising regulated content standards.